Back to Results

Santen Pharmaceutical Co (SNPHY)

Santen Pharmaceutical Co., Ltd. is a Japanese healthcare company focused on pharmaceuticals and medical devices, with operations across Japan, China, wider Asia, Europe, the Middle East, Africa, and other international markets. The company’s research and development, manufacturing, and marketing activities are centered on eye care, including treatments for glaucoma, ocular hypertension, allergic conjunctivitis, vernal keratoconjunctivitis, and related conditions. Its portfolio includes marketed products such as tafluprost/timolol maleate and ciclosporin, along with additional ophthalmic candidates in various stages of development, including late-stage programs for glaucoma and ocular hypertension, ptosis, juvenile myopia, dry eye, and other eye disorders. The listed security is an OTC Markets depositary receipt representing common stock of Santen Pharmaceutical Co.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Altman Z-Score Free Cash Flow / Net Income
OTC-SNPH.Y
$12.61
14.6% Upside
Fair
Not available
Not available
Great
0.0%
November 6, 2026
14.2x
1.8x
1.9x
3.489 B
2.891 B
0.0%
11.7
90.7%
Valuation • Fair Value

Santen Pharmaceutical Co (OTC-SNPH.Y) Fair Value by Valuation Model

Review the available estimates for Santen Pharmaceutical Co (OTC-SNPH.Y), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$12.61

Estimated upside of 14.6% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$13.90

Discounted cash flow valuation reference.

Ben Graham Formula Value

$8.49

Classic Ben Graham valuation formula reference.

EPV Fair Value

$15.41

Earnings power value estimate.

Comps Fair Value

$10.86

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 6 available valuation references for Santen Pharmaceutical Co (OTC-SNPH.Y) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Santen Pharmaceutical Co (OTC-SNPH.Y)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.795 B

Current operating scale indicator.

Revenue Forecast

1.94 B

Forward revenue estimate.

EBITDA

401.9 M

Current operating profitability reference.

EBITDA Forecast

435.8 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Santen Pharmaceutical Co (OTC-SNPH.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Santen Pharmaceutical Co (OTC-SNPH.Y)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.55

No elevated caution signal from this screen.

Altman Z-Score

11.7

Relatively strong balance-sheet zone.

FCF / Net Income

90.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Santen Pharmaceutical Co (OTC-SNPH.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Santen Pharmaceutical Co (OTC-SNPH.Y)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 6, 2026

Days to Earnings

45

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Santen Pharmaceutical Co (OTC-SNPH.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Santen Pharmaceutical Co (OTC-SNPH.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Santen Pharmaceutical Co (OTC-SNPH.Y) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Santen Pharmaceutical Co (OTC-SNPH.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Santen Pharmaceutical Co (OTC-SNPH.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Santen Pharmaceutical Co (OTC-SNPH.Y) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Santen Pharmaceutical Co (OTC-SNPH.Y) Stock FAQ

Data-supported answers about Santen Pharmaceutical Co (OTC-SNPH.Y), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$12.61
Estimated upside 14.6%
Valuation Rating
Undervalued
Estimated upside of 14.6%
Financial Health
Great
Current financial-health read

The current fair value estimate for Santen Pharmaceutical Co (OTC-SNPH.Y) is $12.61. This implies an estimated upside of 14.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 14.6% versus the current market price.

The current financial health read for Santen Pharmaceutical Co (OTC-SNPH.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Santen Pharmaceutical Co (OTC-SNPH.Y) is November 6, 2026.

The latest available data indicates no current dividend yield for Santen Pharmaceutical Co (OTC-SNPH.Y).

The current P/E ratio listed for Santen Pharmaceutical Co (OTC-SNPH.Y) is 14.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Santen Pharmaceutical Co is 3.489 B.

The current enterprise value listed for Santen Pharmaceutical Co is 2.891 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Santen Pharmaceutical Co is OTC-SNPH.Y, and the stock is listed on OTC Markets.

Santen Pharmaceutical Co (OTC-SNPH.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Santen Pharmaceutical Co is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B